Tetanus vaccine - Tianjin CanSino Biotechnology
Alternative Names: Adsorbed tetanus vaccine - Tianjin CanSino Biotechnology; Tetanus vaccine (adsorbed) - Tianjin CanSino Biotechnology; TTVALatest Information Update: 10 Apr 2024
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Tetanus
Most Recent Events
- 20 Mar 2024 Phase-III clinical trials in Tetanus (Prevention) in China (IM) (NCT06120751)
- 14 Nov 2023 CanSino Biologics plans a phase I trial for Tetanus (Prevention) in China (IM, Injection) (NCT06123663)
- 10 Nov 2023 Tianjin CanSino Biotechnology plans a phase III trial in Tetanus (Prevention, In adults, In the elderly) in China (IM) (NCT06120751)